Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
1.800
+0.030 (1.69%)
At close: Apr 19, 2024, 4:00 PM
1.770
-0.030 (-1.67%)
After-hours: Apr 19, 2024, 4:34 PM EDT
Immuneering Stock Forecast
IMRX's stock price has decreased by -86.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Immuneering stock have an average target of 15.75, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 775.00% from the current stock price of 1.80.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +733.33% | Apr 12, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $20 → $8 | Strong Buy | Maintains | $20 → $8 | +344.44% | Apr 2, 2024 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $16 → $3 | Strong Buy → Hold | Downgrades | $16 → $3 | +66.67% | Mar 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 → $16 | Strong Buy | Maintains | $21 → $16 | +788.89% | Mar 15, 2024 |
| Needham | Needham | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +733.33% | Mar 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.27M
EPS This Year
-1.98
from -1.88
EPS Next Year
-1.92
from -1.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 9.1M | n/a | 145.3M | 217.8M |
| Avg | n/a | 1.3M | n/a | 47.1M | 76.5M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 362.8% |
| Avg | - | - | - | - | 62.5% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.98 | -0.87 | -1.42 | -0.53 | 0.75 |
| Avg | -1.98 | -1.92 | -2.12 | -1.87 | -0.52 |
| Low | -2.33 | -2.57 | -2.84 | -3.10 | -1.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.